Our Pipeline

We are utilizing our Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Each of our programs provides opportunities to expand into additional indications beyond the patient populations we are initially targeting. Our lead CAR program, LYL797, is initially being developed for the treatment of ROR1+ non-small cell lung cancer and triple negative breast cancer. LYL845 is expected to be an autologous TIL therapy for the treatment of multiple solid tumors. GSK is developing an NY-ESO-1 TCR T cell product candidate, and we are collaborating to potentially enhance this clinical-stage product candidate.


to Top